Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brimonidine/dorzolamide/timolol - Laboratorios Sophia

Next Previous
Drug Profile

Brimonidine/dorzolamide/timolol - Laboratorios Sophia

Alternative Names: Krytantek PF; PRO-122

Latest Information Update: 21 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Laboratorios Sophia
  • Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Quinoxalines; Small molecules; Sulfonamides; Thiadiazoles; Thiophenes
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Beta adrenergic receptor antagonists; Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ocular hypertension

Most Recent Events

  • 06 Mar 2025 Laboratorios Sophia terminates a phase III non-inferiority trial for Ocular hypertension in patients with open-angle glaucoma in Mexico and Colombia (Opthalmic) due to sponsor's prerogative since initial purpose for study shifted according to business strategy (NCT03193333)
  • 12 Jan 2021 Laboratorios Sophia plans a phase IV trial for Ocular hypertension in patients with open-angle glaucoma (Opthalmic, preservative free solution) in May 2021 (NCT04702789)
  • 22 Oct 2020 Phase III PRO-122LATAM trial is still ongoing for Ocular hypertension in Mexico (NCT03193333)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top